Fingolimod support

Patients prescribed with ^PrTeva-Fingolimod have access to the bilingual Teva-Fingolimod Patient Care Program^SM. By helping patients enrol, you ensure they receive the support they need while taking this medication.

The program contains two key components:

• First-dose monitoring: This is required for all patients starting fingolimod hydrochloride treatment for the first time or restarting treatment if interrupted. It involves observation at a clinic for at least six hours and includes an electrocardiogram for signs and symptoms of bradyarrhythmia.
• Financial support: The Teva-Fingolimod Patient Care Program^SM can offer reimbursement and financial assistance to enroled patients. For patients who qualify, the pharmacy will be reimbursed in the same way as any other third-party plan.

We’ve also created materials to help explain the program and its benefits to patients. These support materials are available as a PDF download—or speak to your Teva Canada Sales Representative to obtain hard copies.

Program enrolment form:  

Use this easy-to-understand form to help your patients enrol. You may also call to enrol at 1-855-868-7622.

Quick-Start portal: 

Alternatively, pharmacies with a valid fingolimod prescription can quickly start a patient enrolment by accessing our Quick-Start Portal. In just a few minutes, an enrolment is initiated and a virtual financial assistance card can be generated for immediate use. The patient will be contacted by the Teva-Fingolimod Patient Care Program to complete the enrolment process and discuss if further assistance beyond the Quick-Start Financial Assistance Card is needed.

If you require assistance or have any questions, contact the program at 1-855-868-7622. We are here to support you.

Program details and how it works: 

Gain a better understanding of the specific operation of the program and reimbursement process.

Patient Q&A bag stuffer: 

Include this bag stuffer to help your patients take home valuable information about the program and generic drugs.